SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares faced downward pressure as the company reported a quarterly revenue miss, prompting intense debate among retail investors regarding the gap between its current valuation and its long-term constellation deployment goals. While bears emphasize the missed earnings and production delays, the community is actively tracking manufacturing cadence, upcoming launch schedules, and government contract wins as key indicators of the stock's future viability.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively bid up shares amidst a perceived supply bottleneck, fueled by labor disputes at Samsung and sustained demand for AI-driven memory infrastructure. The community remains sharply divided, with bulls pointing to a rerating of the stock's valuation and potential for further gains, while bears argue the parabolic move is an overextended bubble driven by sentiment rather than fundamentals.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing extreme volatility and massive volume spikes driven by speculative momentum, leading to intense community debate over whether it is a legitimate short squeeze or a classic pump-and-dump scheme. Investors are closely monitoring its price action and halt status, with many actively discussing the risks and potential for rapid reversals common in low-float, China-based stocks.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is experiencing significant volatility as investors weigh a recent defense contract against ongoing skepticism regarding the company's edge AI performance benchmarks. The community remains sharply divided between those betting on long-term disruption in the defense and autonomous drone sectors and those highlighting concerns over transparency and the long-term viability of their compute-in-memory architecture.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is generating intense community debate as investors weigh the stock's significant decline against robust growth metrics and aggressive insider purchasing by the chairman. While some participants are wary of volatility and the broader fintech sector's susceptibility to delinquency trends, many are accumulating positions in anticipation of a potential squeeze or positive momentum from upcoming earnings and legal developments.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is experiencing heightened volatility and skepticism as retail investors express frustration over a perceived lack of meaningful business execution, recent share dilution, and poor stock performance. While some long-term investors are focused on the company's potential to capitalize on future stablecoin and digital infrastructure developments, the community remains deeply divided, with many actively warning about ongoing dilution risks and the lack of tangible partnership announcements.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is seeing heightened activity as market participants speculate on a potential breakout driven by tight industrial supply chains and increased demand for precious metals in AI infrastructure. Community sentiment remains deeply divided, with bulls pointing to historical supply deficits and long-term storage potential, while others caution that the asset's recent volatility is heavily influenced by geopolitical headlines and macro-correlations with oil and the dollar.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is facing heightened market scrutiny surrounding its upcoming earnings report, with sentiment divided between concerns over past performance and optimism regarding the potential passage of the CLARITY Act. Traders are actively debating whether the stock's recent volatility is a setup for a breakout driven by regulatory catalysts or if the company will continue to struggle with cooling crypto trading volumes.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is rallying as investors react to a bullish earnings transcript and strong institutional interest in its shift from research to commercial hardware, particularly its proprietary TFLN photonic chip technology. The community is actively discussing the stock's significant short interest and the potential for a squeeze, while many are focused on the long-term convergence of quantum and AI infrastructure.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is facing intense volatility following a mixed quarterly earnings report that missed revenue and profit expectations, triggering concerns over margin compression and growth deceleration. Despite the headline miss, the stock is seeing significant community debate as bulls point to raised full-year guidance and a strategic pivot toward branded weight-loss partnerships, while bears warn of a lack of a competitive moat and potential downside risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Volume Explodes, Fundamentals Shift

Today’s market action reflects a striking divergence between speculative momentum, restructuring narratives, and long-term industrial themes. $OMEX, $KBLB, $UCAR, $ELAB, $BBGI, $QNCX

Quince Therapeutics Stock Climbs 8% Over Payment Of $5.5 Mln To Settle EIB Loan

(RTTNews) - Shares of Quince Therapeutics, Inc. (QNCX) are moving up about 8 percent on Monday morning trading after the company announced the settlement of its outstanding obligations under its loan from the European Investment Bank for a payment of $5.5 million...

<ul class="summary-bullets"><li>Quince Therapeutics paid $5.5 million to settle its total debt worth $16.4 million.</li><li>The company had earlier said that it has a runway up to the second half of 2026 if its warrants are exercised.</li><li>The stock has tanked 97% since the company announced disappointing trial results for its treatment of a rare nervous system disorder.</li></ul>Shares of Quince Therapeutics (QNCX) gave up most of their pre-market gains, but traded with almost 10% gains on Monday morning after the company announced it has settled its debt with the European Investment Bank, a move that clears the way for advancing its restructuring efforts.Quince Therapeutics said it paid $5.5 million and, as a result, has settled its total debt worth $16.4 million. With this payment, all commitments under both the loan and settlement agreements have been fully satisfied.“By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives, including, but not limited to, merger, reverse merger, asset sale, or other strategic transactions,” said CEO Dirk Thye.&nbsp;The company had earlier appointed LifeSci Capital as its exclusive financial advisor to assist with the restructuring.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.Users speculated a potential merger after the debt was cleared.<stembedurl>https://stocktwits.com/SuellenD/message/648925162</stembedurl><stembedurl>https://stocktwits.com/andrew011/message/648923227</stembedurl><h2 class="st-heading-2">Stock Sinks After Disappointing Phase 3 Results</h2>In January, Quince Therapeutics’ Phase 3 NEAT trial evaluating eDSP in patients with Ataxia-Telangiectasia, a rare disorder impacting the nervous and immune systems, missed its primary and key secondary endpoints. <a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has since crashed more than 97%.According to its last financial filing for the quarter ended Sept. 30, 2025, the company reported $26.3 million in cash and investments. The funds are expected to support operations through the second quarter of 2026, but could be extended into the second half of 2026 if its warrants are fully exercised.Last year, the company raised about $11.5 million in upfront funding through a financing round, with the potential to secure an additional $10.4 million if the associated warrants are fully exercised for cash.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger

Quince Therapeutics Inc (QNCX) cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Equity

The company cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the companys outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5...

What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours

Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans. read more...

Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today

QNCX, SPOT, SPGI, INTC, DDOG were among the stocks trending among investors on Tuesday, Feb. 10, 2026.read more...

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic...

Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease

Quince Therapeutics shares plunged nearly 90% after its Phase 3 trial for a rare genetic disorder missed primary and secondary goals, despite showing no major safety concerns.read more...

Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp

Citizens Jmp cut shares of Quince Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday...

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

QNCX
Quince Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest QNCX News

QNCXQuince Therapeutics Inc